Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.52 |
| ▸ | CCR1 | P32246 | 3/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156889 | 0.87 | CCR1 (0.50) | EPHX2CCR1PTGDR2 | |
| SCHEMBL6758395 | 0.87 | CCR1 (0.50) | EPHX2CCR1PTGDR2 | |
| SCHEMBL6156882 | 0.87 | CCR1 (0.50) | EPHX2CCR1PTGDR2 | |
| SCHEMBL6442642 | 0.86 | CCR1 (0.55) | EPHX2CCR1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL6155693 | 0.84 | CCR1 (0.49) | EPHX2CCR1PTGDR2 | |
| SCHEMBL6155698 | 0.84 | CCR1 (0.49) | EPHX2CCR1PTGDR2 | |
| SCHEMBL6077870 | 0.84 | CCR1 (0.57) | CCR1PTGDR2SMN1; SMN2 | |
| SCHEMBL6441529 | 0.79 | EPHX2 (0.54) | EPHX2MEN1ALDH1A1KMT2AMLNR | |
| SCHEMBL6763204 | 0.79 | CCR1 (0.42) | EPHX2CCR1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL6763208 | 0.79 | CCR1 (0.42) | EPHX2CCR1PTGDR2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063759-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | EPHX2 3153/4885CCR1 1/4885PTGDR2 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.